# US 2025/0208136 A1 · Peptides and combinations of peptides for use in immunotherapy against oropharyngeal squamous cell carcinoma (OPSCC) and other cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0208136 A1
- Document ID: US20250208136A1
- Status: Published application
- Kind: A1
- Application number: 19/039,730
- Filed: 2025-01-28
- Published: 2025-06-26
- Earliest claimed: 2022-07-29
- Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät
- Inventors: Simon Laban; Lena Mühlenbruch; Juliane Walz; Hans-Georg Rammensee; Thomas Hoffmann
- Web page: https://patentgrep.com/patent/US20250208136A1

## CPC

- C07K 16/18: against material from animals or humans
- G01N 33/56977: {HLA or MHC typing}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 16/084: Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/708: {for papilloma}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of oropharyngeal squamous cell carcinoma (OPSCC). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A pharmaceutical composition for the prevention or treatment or diagnosis of oropharyngeal squamous cell carcinoma (OPSCC), comprising at least one peptide which binds to class II molecules of the major histocompatibility complex (MHC class II molecules) or induces T cells cross-reacting with said peptide, and a pharmaceutically acceptable carrier, wherein said at least one peptide comprises an amino acid sequence which is selected from the group consisting of: SEQ ID NO: 1 to SEQ ID NO: 14 and variant sequences thereof which are at least 88% homologous to SEQ ID NO: 1 to SEQ ID NO: 14, wherein said peptide is preferably not a full-length polypeptide.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein it comprises at least 2 to at least 9 different peptides, each peptide comprising an amino acid sequence which is selected from the group consisting of: SEQ ID NO: 1 to SEQ ID NO: 14 and variant sequences thereof which are at least 88% homologous to SEQ ID NO: 1 to SEQ ID NO: 14, wherein said peptide is preferably not a full-length polypeptide.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein it comprises different peptides comprising the following amino acid sequences:
(SEQ ID NO: 1)
IRQFTSSSSIKGSSG
(SEQ ID NO: 2)
LTSTSGPGFHLMLPFI
(SEQ ID NO: 3)
ELKKKLKEKAKERREKEMLERLEK
(SEQ ID NO: 4)
ENDVIISINGQSVVS
(SEQ ID NO: 5)
IQDFIEAEDDLSSFR
(SEQ ID NO: 6)
PVHWQFGQLDQHPIDG
(SEQ ID NO: 7)
FADFTFATGKIIG
(SEQ ID NO: 8)
IKNIISEYKSAIQSQKRRRPRYRKR
(SEQ ID NO: 9)
VDEEEVKFPGTNFDE.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein it comprises at least one additional peptide which binds to class I molecules of the major histocompatibility complex (MHC class I molecules) or induces T cells cross-reacting with said peptide, wherein said at least one additional peptide comprises an amino acid sequence which is selected from the group consisting of: SEQ ID NO: 15 to SEQ ID NO: 62 and variant sequences thereof which are at least 88% homologous to SEQ ID NO: 15 to SEQ ID NO: 62, wherein said peptide is preferably not a full-length polypeptide.

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the at least one additional peptide is selected depending on the MHC class I allotype of the individual to be treated.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the at least one additional peptide is selected as follows:
MHC class I allotype
Amino acid sequence of peptide
A*02:01
SEQ ID NO: 15 to SEQ ID NO: 24
A*01:01
SEQ ID NO: 25 to SEQ ID NO: 31
A*03:01
SEQ ID NO: 32
A*24:02
SEQ ID NO: 33 to SEQ ID NO: 35
A*11:01
SEQ ID NO: 36
B*07:02
SEQ ID NO: 37 to SEQ ID NO: 38
B*51:01
SEQ ID NO: 39 to SEQ ID NO: 41
B*08:01
SEQ ID NO: 42 to SEQ ID NO: 45
B*44:02
SEQ ID NO: 46 to SEQ ID NO: 48
B*40:01
SEQ ID NO: 49 to SEQ ID NO: 53
C*07:01
SEQ ID NO: 54 to SEQ ID NO: 55
C*07:02
SEQ ID NO: 56
C*04:01
SEQ ID NO: 57 to SEQ ID NO: 58
C*03:04
SEQ ID NO: 59 to SEQ ID NO: 61
A*02:01
SEQ ID NO: 62,
wherein the amino acid sequences of each MHC class I allotype group includes variant sequences which are at least 88% homologous.

### Claim 7 (depends on 4)

The pharmaceutical composition according to claim 4, wherein it comprises at least 2 to at least 6 different additional peptides, each additional peptide comprising an amino acid sequence which is selected from the group consisting of: SEQ ID NO: 15 to SEQ ID NO: 62 and variant sequences thereof which are at least 88% homologous to SEQ ID NO: 15 to SEQ ID NO: 62, wherein said additional peptide is preferably not a full-length polypeptide.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, which is a vaccine.

### Claim 9

A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 62, and variant sequences thereof which are at least 88% homologous to SEQ ID NO: 1 to SEQ ID NO: 62, and wherein said variant binds to molecule(s) of the major histocompatibility complex (MHC) or induces T cells cross-reacting with said variant peptide; and a pharmaceutical acceptable salt thereof, wherein said peptide is preferably not a full-length polypeptide.

### Claim 10 (depends on 9)

The peptide according to claim 9, wherein said peptide has the ability to bind to an MHC class I or II molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.

### Claim 11 (depends on 9)

The peptide or variant thereof according to claim 9, wherein the amino acid sequence thereof comprises a continuous stretch of amino acids according to any one of SEQ ID NO: 1 to SEQ ID NO: 62.

### Claim 12 (depends on 9)

A T cell receptor or a fragment thereof, that is reactive with an HLA ligand when bound to an MHC molecule, wherein said HLA ligand is the peptide or variant thereof according to claim 9.

### Claim 13 (depends on 9)

A nucleic acid encoding for a peptide or variant thereof according to claim 9.

### Claim 14 (depends on 13)

A recombinant host cell comprising the nucleic acid according to claim 13.

### Claim 15 (depends on 9)

An in vitro method for producing activated T lymphocytes, the method comprising contacting in vitro T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide according to claim 9.

### Claim 16 (depends on 9, 15)

An activated T lymphocyte, produced by the method according to claim 15, that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence given in claim 9.

### Claim 17 (depends on 9)

A kit comprising:
(a) a container comprising the peptide according to claim 9 in lyophilized formulation; and
(b) a second container containing a diluent or reconstituting solution for the lyophilized formulation.

### Claim 18 (depends on 9)

A method for producing a personalized anti-cancer vaccine, said method comprising:
a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from an individual patient;
b) comparing the peptides as identified in step a) with a warehouse of peptides which have been pre-screened for immunogenicity and/or over-presentation in tumors as compared to normal tissues;
c) selecting at least one peptide from the warehouse that matched a TUMAP identified in said patient; and
d) formulating the personalized vaccine based on step c),
wherein said warehouse comprises a plurality of peptides or variant sequences according to claim 9.
